The breast-fed infant is the gold standard for infant formula research and development. The addition of long-chain polyunsaturated fatty acids and nucleotides to formula are intended to promote visual, neuro and immune development. Studies in both preterm and term infants have not consistently demonstrated efficacy with long-chain polyunsaturated fatty acids supplementation of infant formulas. Explanations for why these supplemented formulas do not always produce visual or neurodevelopmental advantages, include a small individual effect or that only a proportion of infants will benefit or the presence of confounding variables. The efficacy of nucleotides has been studied by analyzing response to vaccination in infants fed human milk versus formulas with or without additional nucleotides. Nucleotide supplemented formulas appear to enhance immune response similar to breast-fed infants with immunization. Humanizing formula with safe and well-studied nutrients may provide benefits that are discovered long after initial trials are concluded.
The health of the breast-fed infant is used as the gold standard for infant formula research and development. The research strategy has been to identify gaps between formula-fed and breast-fed infants in physiology and outcomes. This has led to proposed interventions to close the gap with new ingredients, processing and feeding systems.
However, the challenges with such an approach are daunting. For example, human milk has unmatchable components and biologic variability from one mothers' milk to another, even within samples of a single feeding. When 'matching' human milk a formula may use ingredients and not just nutrients. Furthermore, because the bioavailability of some nutrients may be altered by processing, they cannot be added to formula and will only exist in human milk.
Two additions to infant formulas to 'close the gap' between formula feeding and breast-feeding include long-chain polyunsaturated fatty acids (LCPUFA) and nucleotides (NT). These nutrients found in human milk enhance visual, neuro-and immune development. The purpose of this article is to look at the evidence surrounding the addition of docosahexanoic acid (DHA), arachidonic acid (ARA) and NT to infant formulas.
Long-chain polyunsaturated fatty acids Background Dietary fat in infancy is fundamental for the provision of energy for rapid growth, fat-soluble vitamins, and essential fatty acids (EFA). The type of fat required is controversial and interest has recently focused on the importance of LCPUFA, such as DHA and ARA. These fatty acids are found in high proportions in the structural lipids of cell membranes, particularly those of the central nervous system, and their accretion primarily occurs during the last trimester of pregnancy and the first year of life. 1 During pregnancy, DHA and ARA cross the placenta to the fetus. Postnatally these fatty acids are supplied in breast milk, which contains a full complement of all polyunsaturated fatty acids (PUFAs) including precursors and metabolites. Infant formulas containing only the precursor EFA, alpha linolenic acid (ALA), omega-3 precursor, linoleic acid (LA), and omega-6 precursor, require that infants synthesize their own DHA and ARA, respectively. Biochemical studies in both term and preterm infants indicate that formula-fed infants had significantly less DHA and ARA in their erythrocytes relative to those fed breast milk. 2 This suggested that infant formulas containing only LA and ALA may not be effective in meeting the full EFA requirements of infants.
Biochemical studies of LCPUFA are clinically relevant as dietary fatty acid supply may affect physiological function. The main areas of interest are the effects of LCPUFA supplementation on visual function, development, and growth.
LCPUFA supplementation in term infants
Two recent reviews by Gibson et al. 3 and Uauy et al. 4 provide a comprehensive review examining the efficacy and safety of adding either DHA or ARA to formulas for term infants.
All trials reviewed involved healthy term infants fed formulas from near birth and most had a breast-fed reference group. Most trials had adequate randomization and masking procedures and also provided power calculations for their primary outcome measurements. 3, 4 Visual evoke potentials (VEP) and Teller acuity cards were used to measure the outcome of vision. Benefits of LCPUFAs were seen in studies with limited sample sizes. [5] [6] [7] The effect on vision in these studies appears to be transient.
However, the Birch et al. 8 study indicated a persistent benefit on visual acuity development for the first year of life in DHA supplemented, formula-fed infants compared with infants fed formula with ample ALA but devoid of LCPUFA. Formula was fed for the first 17 weeks of life. The DHA and ARA used in formula were derived from single-cell oils. The dietary effects on visual acuity development were evident with the use of sweep VEP acuities, but absent if behavioral measurements (Teller acuity) were used.
Scores on Bayley Mental Development Index II (MDI) at 18 months of age for the DHA-ARA and the breast milk group were significantly better than that observed in the non-LCPUFA formula-fed infants. A 7-point normalized MDI score difference was highly significant despite a relatively small sample size (n ¼ 20). 8 Auestad et al. 9 compared visual function in infants fed standard formula (n ¼ 26) supplemented with DHA from marine oil (n ¼ 28) or formula with both DHA and ARA. No significant difference in visual acuity was noted among the three diet groups during the 12-month trial. There was also no benefit in language development at 14 months as measured by the MacArthur Communicative Development Inventory. 10 Large controlled studies by Lucas et al., 11 Auestad et al., 12 and Makrides et al. 13 all failed to detect effects of LCPUFA supplementation on Bayley's Scales of Infant Development. Possible interpretations of these data include a small individual effect (type 2 error) or that only a proportion of infants will benefit or the presence of confounding variables. Further studies are needed to elucidate this issue.
There is little evidence for n-3 LCPUFA supplementation of term formulas causing perturbations in growth. The safety of LCPUFA-supplemented formulas for term infants have been further highlighted by the Lucas trial, 11 which reported similar rates of atopy and infections in infants fed either standard or LCPUFA-supplemented formulas.
LCPUFA supplementation in preterm infants
The literature including randomized control trials designed to test the efficacy and safety of varying levels of eicosapentanoic acid (EPA, nÀ3), DHA, and ARA supplementation in preterm infants are reviewed extensively by Gibson. 3 All trials involved healthy preterm infants, fed formula, and most included a breast-fed reference group. Not all trials were analyzed on an intention to treat basis, with infants developing complications after randomization either being excluded or withdrawn from the data analysis.
Two studies by Carlson co-workers 14,15 using different supplement duration (2 months and 12 months, respectively), found transient improvement at 2 and 4 months using Teller cards to measure visual acuity. Hansen et al. 16 also using Teller acuity cards found no difference between supplemented and controls at 2 and 4 months post-term.
Uauy co-workers 17 measured visual acuity at 2 months postterm using VEP and Teller acuity cards and reported that LCPUFA supplemented infants had better visual acuity. Innis et al. O'Connor et al. 19 measured visual acuity by Teller acuity cards at 2, 4 and 6 months post-term and found no difference between supplemented and control groups. However, swept-parameter VEP was better in the supplemented groups compared with the control groups in a subgroup of infants at 6 months post-term.
Development assessed by the Fagan Infantest of Development at 12 months in the Carlson et al. studies 14, 15 suggested better cognition in the supplemented group. However, mean psychomotor developmental index was lower in the supplemented group. 15 Fewtrell et al. 20 reported Bayley Scales of Infant Development (BSID) and Knoblock, Passamanik, and Sherrard's Developmental Screening Inventory at 9 and 12 months and found no difference between groups. O'Connor et al. 19 measured BSID at 12 months and van Wezel-Meijler et al. 21 at 12 and 24 months post-term and found no significant differences between groups. Meta-analysis of BSID of three studies at 12 months shows no significant effect of supplementation on development. [19] [20] [21] The effect of supplementation on growth of preterm infants producing impaired growth was reported in three trials. 15, 22, 23 These studies suggested supplemented infant formula with fish oil produced negative effects on growth. The possibility that fish oil treatment had negative effects on growth through a lowering of ARA remains a significant cause for concern, although all the studies assessing fish oil supplementation and growth had flaws that could have influenced growth outcomes. Five recent trials adding ARA along with n-3 LCPUFA to avoid the decline in plasma and erythrocyte ARA caused by fish oil supplementation have reported no detrimental effects on growth. [24] [25] [26] [27] [28] Clandinin et al. 28 and Groh-Wargo et al. 29 have added to the growth literature by demonstrating that growth was not only improved with algal and fungal oils 28 in preterm infants, but also that DHA and ARA supplemented formulas fed to infants up to 1 year of age led to increased lean body mass and reduced fat mass by 1 year of age. 29 In addition, the improved growth was also accompanied by improved Bayley mental and psychomotor development at 118 weeks postmenstual age versus controls. 28 Dietary NT NT have been added to formulas for term infants in the US since the mid-1980s, and to formulas for preterm infants since 2002. The primary justification for these additions was evidenced in animals and humans. There is evidence which supports the concepts that dietary NT enhance development of the gastrointestinal and immune systems. 30, 31 A lower incidence of diarrhea, 32-34 enhanced response to vaccination, 33, 35, 36 and immune cell subset distribution 37, 38 have been reported in term infants with formula supplemented with NT.
The NT formulation added to formulas for infants provides a blend that mimics the potentially available nucleotide content of human milk, 33 with the intent being to support development of the infant immune system the first year of life analogous to the effects of human milk.
Unfortunately, there are no published studies in which large numbers of preterm infants were fed formulas that differed only in NT content. O'Connor et al. 19 conducted a multi-center, randomized trial to investigate the effects of LCPUFA supplementation on very low-birth-weight preterm infants; more than 100 infants were enrolled into each group. Both the study and the control formulas contained added NT. A reference group of human milk-fed infants was also included. As the study and control formulas both contained added NT, these data do not address efficacy issues related to dietary NT. The similar incidence of adverse events between the human milk-fed and the formula-fed groups provides presumptive evidence of the safety of NT-supplemented formula for preterm infants.
Summary
A review by the Cochrane Database of Systemic Reviews concerning LCPUFAs in preterm infants concluded that infants enrolled in the trials meriting review were relatively mature and healthy preterm infants and that 'no long term benefits were demonstrated for infants receiving formula supplemented with LCPUFA. 39 Yet, closing the dietary gap between formula and human milk and doing it safely still seems to be valuable. For example, taurine blood levels in preterm infants obtained in a 1980's cohort only recently in 2004 was linked to the improvement in mental developmental index scores at 18 months and standardized math tests at 8 years of age in preterm infants. The enhanced scores were linked to taurine in human milk and preterm formula supplemented with taurine. 40 Taurine was added to preterm formulas but not term formulas to humanize formula prior to this study.
Blood pressure is lower in breastfed children than those fed formula as infants. It is also likely that these differences carry through into adulthood, which would have significant impact on public health issues including cardiovascular disease and stroke. Dietary omega-3 fatty acid supplementation can lower blood pressure in adults. 41 A study of term infants in an original trial on LCPUFA supplemented formula controls, and a reference breast milk group found lower blood pressure in later childhood with supplementation with LCPUFAs during infancy. 42 Will this prove to have similar public health implication as human milk feeding?
These two examples, taurine and LCPUFAs addition to humanize formula teach us that while human milk has unmatchable components, research aimed at 'discovering' the wonders of human milk are crucial to improve the health of infants who are not exclusively breast-fed.
